AI Article Synopsis
- Rosmarinic Acid (RA) has various biological benefits, including antioxidant and anti-inflammatory properties, and this study investigates its effect on the Herpes simplex virus type 1 (HSV-1) using Zataria multiflora.
- The methanolic extract of Z. multiflora was standardized for RA content and tested in vitro on vero cells, showing a significant reduction in viral plaque formation, particularly at higher concentrations.
- The study concluded that the presence of rosmarinic acid plays a crucial role in the antiviral activity of Z. multiflora against HSV-1.
Article Abstract
In Rosmarinic Acid (RA) is a phenolic acid which has many biological activities such as antioxidant, anti inflammatory and anti viral effects. In the present study, we have studied the anti Herpes simplex type 1 (HSV-1) effect of methanolic extract of Zataria multiflora which has been standardized on the basis of RA content. Methanolic extract of Zatria multiflora was prepared by maceration method. RA content of plant extract was measured by spectrophotometry method using the calibration curve of RA. Maximum non Toxic Concentration (MNTC) of the plant was determined by neutral red method. MNTC and lower serial dilutions of extract were examined in vitro on vero cells for their effect against HSV-1 using a plaque reduction assay. Acyclovir was used as positive control. Time-dependent antiviral effect of Z. multiflora was studied by adding the extract to HSV-1 infected vero cells at different stages of infection. The percentage of RA was determined as 2.2% in Z. multiflora. This plant was effective in all used concentrations and significantly reduced plaque formation up to 100% at concentrations of 800 and 1000 microg mL(-1). Clearly Z. multiflora revealed both a time and concentration inhibition. It seems that the presence of rosmarinic acid would be a determining factor for anti HSV activity of Z. multiflora.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3923/pjbs.2013.180.184 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tofacitinib Treatment for Active Dermatomyositis and Anti-synthetase Syndrome: A Prospective Cohort Pilot Study.
Rheumatology (Oxford)
January 2025
Department of Rheumatology and Immunology and Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People's Hospital, Beijing, 100044, China.
Objectives: The objective of this study was to evaluate the efficacy and safety of tofacitinib in the treatment of active dermatomyositis (DM) and anti-synthetase syndrome (ASS).
Methods: Tofacitinib was administered at a dose of 5 mg twice daily to patients who exhibited inadequate response to conventional treatments. The primary end point was the reduction of T follicular helper (Tfh) cells at week 24.
Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice.
Expert Rev Vaccines
January 2025
Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Introduction: Vaccines to prevent important infections involving, e.g. influenza viruses, severe acute respiratory syndrome-causing coronaviruses (e.
View Article and Find Full Text PDFUltrasound-guided thoracic paravertebral injection of dexamethasone palmitate combined with ropivacaine for the treatment of thoracic herpes zoster-related pain: protocol for a prospective, randomized controlled, single-center study.
Front Pharmacol
January 2025
Department of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Background: Herpes zoster (HZ) patients often experience herpes zoster-associated pain (ZAP). Thoracic paravertebral nerve block has been proven effective in relieving ZAP and reducing the incidence of postherpetic neuralgia (PHN). Compared to dexamethasone, dexamethasone palmitate (DXP) has stronger anti-inflammatory effects, a longer duration of action, and fewer adverse reactions.
View Article and Find Full Text PDFNovel Hsp90α inhibitor inhibits HSV-1 infection by suppressing the Akt/β-catenin pathway.
Int J Antimicrob Agents
January 2025
School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China. Electronic address:
The prevalence of herpes simplex virus type 1 (HSV-1) infection and the emergence of drug-resistant HSV-1 strains posts a significant global health challenge, necessitating the urgent development of effective anti-HSV-1 drugs. As one of the most prevalent molecular chaperones, heat shock protein 90 α (Hsp90α) has been extensively demonstrated to regulate a range of viral infections, thus representing a promising antiviral target. In this study, we identified JD-13 as a novel Hsp90α inhibitor and explored its capability in inhibiting HSV-1 infection.
View Article and Find Full Text PDFEfficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease.
Rheumatology (Oxford)
January 2025
Nephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan.
Objectives: To evaluate the efficacy and safety of first-line targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) in patients with rheumatoid arthritis (RA) and chronic kidney disease (CKD).
Methods: This retrospective cohort study included 216 patients with RA prescribed their first tsDMARDs at two hospitals between 2013 and 2022. Dose reduction and contraindication guidelines for tsDMARDs according to kidney function were followed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!